NCT04094311 2026-04-20
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
Clinical Trials
14 trialsNCT04404283 2026-04-20
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT06717347 2026-04-16
MK-2140-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT01804686 2026-04-13
CAN3001
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT03570892 2026-04-08
BELINDA
Novartis
Phase 3 Completed
NCT04231448 2026-04-08
DEB
Chipscreen Biosciences, Ltd.
Phase 3 Completed
NCT04628494 2026-04-08
EPCORE DLBCL-1
Genmab
Phase 3 Active not recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT07226752 2026-04-08
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab
Phase 3 Active not recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT07409428 2026-04-01
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
Phase 3 Recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT07493109 2026-03-25
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
The First Hospital of Jilin University
Phase 3 Recruiting